Please login to the form below
NTDT
This page shows the latest NTDT news and features for those working in and with pharma, biotech and healthcare.
Novartis' Exjade gets EU approval for thalassaemia
Novartis' Exjade (deferasirox) has received European approval as a treatment for non-transfusion-dependent thalassaemia (NTDT) syndromes, a group of genetic disorders characterised by red blood cell problems and anaemia. ... This approval is a critical
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Featured jobs
- Head of Partnerships - Competitive - London
-
Competitive Salary Offered
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Senior Medical Writer
-
Salary TBC
-
Midweight Brand Planner
-
Up to £50, 000
Subscribe to our email news alerts
- Verily unveils next-gen trials alliance with Novartis, Pfizer
- Syncona launches another cell therapy company, Treg specialist Quell
- Keytruda monotherapy fails in triple negative breast cancer
- Moving annual total (MAT)
- Europe responding to gene therapy challenge, but picture remains fragmented
- Key success factor (KSF)
PMHub
Synergy Vision
Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...
Latest intelligence
- Playing Mind Games
- To give a brief strong direction, we need to ascertain how the brand intends to win attention, how it will engage, what its call to action will be and how...
- PM Society Digital Award Finalists
- P&P are shortlisted for the ‘Craft in Film’ category at this year’s PM Society Digital Awards...
- The Exhibition Hall: Past, Present and Future
- As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Quick links
Infographics
